Eisai Co (TSE:4523) Change In Receivables : 円0 Mil (TTM As of Dec. 2023)

View and export this data going back to 1961. Start your Free Trial

What is Eisai Co Change In Receivables?

Eisai Co's change in receivables for the quarter that ended in Dec. 2023 was 円0 Mil. It means Eisai Co's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Eisai Co's change in receivables for the fiscal year that ended in Mar. 2023 was 円0 Mil. It means Eisai Co's Accounts Receivable stayed the same from Mar. 2022 to Mar. 2023 .

Eisai Co's Accounts Receivable for the quarter that ended in Dec. 2023 was 円186,182 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Eisai Co's Days Sales Outstanding for the three months ended in Dec. 2023 was 95.60.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Eisai Co's liquidation value for the three months ended in Dec. 2023 was 円37,933 Mil.

Eisai Co Change In Receivables Historical Data

The historical data trend for Eisai Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co Change In Receivables Chart

Eisai Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Change In Receivables

Get a 7-Day Free Trial

Eisai Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Eisai Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

Eisai Co (TSE:4523) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Eisai Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	186182	/	177703	*	91
=	95.60

2. In Ben Graham's calculation of liquidation value, Eisai Co's accounts receivable are only considered to be worth 75% of book value:

Eisai Co's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	285192	-	468519	+	0.75 * 186182	+	0.5 * 163246
=	37,933

Eisai Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Eisai Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Eisai Co (TSE:4523) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (TSE:4523) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ESAIY:USA ESALF:USA EII:Germany

Address

4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088

Website

http://www.eisai.co.jp

Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Eisai Co (TSE:4523) Headlines

No Headlines